Cargando…
Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity
Autores principales: | Lee, Ho Jin, Pham, Phuong Chi, Hyun, Seung Yeob, Baek, Byungyeob, Kim, Byungjin, Kim, Yunha, Min, Hye-Young, Lee, Jeeyeon, Lee, Ho-Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018920/ https://www.ncbi.nlm.nih.gov/pubmed/36927387 http://dx.doi.org/10.1186/s12943-023-01754-6 |
Ejemplares similares
-
Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity
por: Lee, Ho Jin, et al.
Publicado: (2018) -
Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor
por: Lee, Ho Jin, et al.
Publicado: (2021) -
Synthesis and Characterization of Two Novel Organic-Inorganic Compounds Based on Tetrahexyl and Tetraheptyl Ammonium Ions and the Preyssler Anion and Their Catalytic Activities in the Synthesis of 4-Aminopyrazolo[3,4-d]- Pyrimidines
por: Bamoharram, Fatemeh Farrash
Publicado: (2010) -
Synthesis and Anticancer Activity of Some New Pyrazolo[3,4-d]pyrimidin-4-one Derivatives
por: Abdellatif, Khaled R. A., et al.
Publicado: (2014) -
Identification and Biological Characterization of the Pyrazolo[3,4-d]pyrimidine Derivative SI388 Active as Src Inhibitor
por: Contadini, Claudia, et al.
Publicado: (2023)